AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer von Jänne, Pasi A, Yang, James Chih-Hsin, Kim, Dong-Wan, Planchard, David, Ohe, Yuichiro, Ramalingam, Suresh S, Ahn, Myung-Ju, Kim, Sang-We, Su, Wu-Chou, Horn, Leora, Haggstrom, Daniel, Felip, Enriqueta, Kim, Joo-Hang, Frewer, Paul, Cantarini, Mireille, Brown, Kathryn H, Dickinson, Paul A, Ghiorghiu, Serban, Ranson, Malcolm

Volltext

Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC von Tsuboi, Masahiro, Herbst, Roy S., John, Thomas, Kato, Terufumi, Majem, Margarita, Grohé, Christian, Wang, Jie, Goldman, Jonathan W., Lu, Shun, Su, Wu-Chou, de Marinis, Filippo, Shepherd, Frances A., Lee, Ki Hyeong, Le, Nhieu Thi, Dechaphunkul, Arunee, Kowalski, Dariusz, Poole, Lynne, Bolanos, Ana, Rukazenkov, Yuri, Wu, Yi-Long

Volltext

Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim result... von Sequist, Lecia V, Han, Ji-Youn, Ahn, Myung-Ju, Cho, Byoung Chul, Yu, Helena, Kim, Sang-We, Yang, James Chih-Hsin, Lee, Jong Seok, Su, Wu-Chou, Kowalski, Dariusz, Orlov, Sergey, Cantarini, Mireille, Verheijen, Remy B, Mellemgaard, Anders, Ottesen, Lone, Frewer, Paul, Ou, Xiaoling, Oxnard, Geoffrey

Volltext

Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations von SEQUIST, Lecia V, YANG, James Chih-Hsin, SU, Wu-Chou, BENNOUNA, Jaafar, KATO, Terufumi, GORBUNOVA, Vera, KI HYEONG LEE, SHAH, Riyaz, MASSEY, Dan, ZAZULINA, Victoria, SHAHIDI, Mehdi, SCHULER, Martin, YAMAMOTO, Nobuyuki, O'BYRNE, Kenneth, HIRSH, Vera, MOK, Tony, GEATER, Sarayut Lucien, ORLOV, Sergey, TSAI, Chun-Ming, BOYER, Michael

Volltext

Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component von Yang, James Chih-Hsin, Ahn, Myung-Ju, Kim, Dong-Wan, Ramalingam, Suresh S, Sequist, Lecia V, Su, Wu-Chou, Kim, Sang-We, Kim, Joo-Hang, Planchard, David, Felip, Enriqueta, Blackhall, Fiona, Haggstrom, Daniel, Yoh, Kiyotaka, Novello, Silvia, Gold, Kathryn, Hirashima, Tomonori, Lin, Chia-Chi, Mann, Helen, Cantarini, Mireille, Ghiorghiu, Serban, Jänne, Pasi A

Volltext

Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR -Mutated Non-Small Cell Lung Cancer von Jänne, Pasi A, Baik, Christina, Su, Wu-Chou, Johnson, Melissa L, Hayashi, Hidetoshi, Nishio, Makoto, Kim, Dong-Wan, Koczywas, Marianna, Gold, Kathryn A, Steuer, Conor E, Murakami, Haruyasu, Yang, James Chih-Hsin, Kim, Sang-We, Vigliotti, Michele, Shi, Rong, Qi, Zhenhao, Qiu, Yang, Zhao, Lihui, Sternberg, David, Yu, Channing, Yu, Helena A

Volltext

Phase 1 study of capmatinib in MET‐positive solid tumor patients: Dose escalation and expansion of selected cohorts von Bang, Yung‐Jue, Su, Wu‐Chou, Schuler, Martin, Nam, Do‐Hyun, Lim, Wan Teck, Bauer, Todd M., Azaro, Analia, Poon, Ronnie Tung Ping, Hong, David, Lin, Chia‐Chi, Akimov, Mikhail, Ghebremariam, Samson, Zhao, Sylvia, Giovannini, Monica, Ma, Brigette

Volltext

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phas... von Yang, James Chih-Hsin, Prof, Wu, Yi-Long, Prof, Schuler, Martin, Prof, Sebastian, Martin, MD, Popat, Sanjay, FRCP, Yamamoto, Nobuyuki, Prof, Zhou, Caicun, Prof, Hu, Cheng-Ping, Prof, O'Byrne, Kenneth, Prof, Feng, Jifeng, Prof, Lu, Shun, Prof, Huang, Yunchao, Prof, Geater, Sarayut L, MD, Lee, Kye Young, Prof, Tsai, Chun-Ming, Prof, Gorbunova, Vera, Prof, Hirsh, Vera, Prof, Bennouna, Jaafar, Prof, Orlov, Sergey, Prof, Mok, Tony, Prof, Boyer, Michael, Prof, Su, Wu-Chou, Prof, Lee, Ki Hyeong, Prof, Kato, Terufumi, MD, Massey, Dan, MSc, Shahidi, Mehdi, MD, Zazulina, Victoria, MD, Sequist, Lecia V, MD

Volltext

Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-... von Miller, Vincent A, Prof, Hirsh, Vera, MD, Cadranel, Jacques, Prof, Chen, Yuh-Min, MD, Park, Keunchil, Prof, Kim, Sang-We, Prof, Zhou, Caicun, Prof, Su, Wu-Chou, Prof, Wang, Mengzhao, Prof, Sun, Yan, Prof, Heo, Dae Seog, Prof, Crino, Lucio, Prof, Tan, Eng-Huat, MD, Chao, Tsu-Yi, Prof, Shahidi, Mehdi, MD, Cong, Xiuyu Julie, PhD, Lorence, Robert M, MD, Yang, James Chih-Hsin, Prof

Volltext

Elucidating Quantum Confinement in Graphene Oxide Dots Based On Excitation-Wavelength-Independent Photoluminescence von Yeh, Te-Fu, Huang, Wei-Lun, Chung, Chung-Jen, Chiang, I-Ting, Chen, Liang-Che, Chang, Hsin-Yu, Su, Wu-Chou, Cheng, Ching, Chen, Shean-Jen, Teng, Hsisheng

Volltext

Iron oxide@chlorophyll clustered nanoparticles eliminate bladder cancer by photodynamic immunotherapy-initiated ferroptosis and immunostimulation von Chin, Yu-Cheng, Yang, Li-Xing, Hsu, Fei-Ting, Hsu, Che-Wei, Chang, Te-Wei, Chen, Hsi-Ying, Chen, Linda Yen-Chien, Chia, Zi Chun, Hung, Chun-Hua, Su, Wu-Chou, Chiu, Yi-Chun, Huang, Chih-Chia, Liao, Mei-Yi

Volltext

The impact of EGFR mutations on the incidence and survival of stages I to III NSCLC patients with subsequent brain metastasis von Chang, Wei-Yuan, Wu, Yi-Lin, Su, Po-Lan, Yang, Szu-Chun, Lin, Chien-Chung, Su, Wu-Chou

Volltext

Prognostic Value of Whole-Body Total Lesion Glycolysis at Pretreatment FDG PET/CT in Non―Small Cell Lung Cancer von CHEN, Helen H. W, CHIU, Nan-Tsing, SU, Wu-Chou, GUO, How-Ran, LEE, Bi-Fang

Volltext

Biocompatible hole scavenger-assisted graphene oxide dots for photodynamic cancer therapy von Shih, Chun-Yan, Huang, Wei-Lun, Chiang, I-Ting, Su, Wu-Chou, Teng, Hsisheng

Volltext

Rab37 in lung cancer mediates exocytosis of soluble ST2 and thus skews macrophages toward tumor‐suppressing phenotype von Tzeng, Hong‐Tai, Su, Ching‐Chin, Chang, Chih‐Peng, Lai, Wu‐Wei, Su, Wu‐Chou, Wang, Yi‐Ching

Volltext

Rab37 mediates trafficking and membrane presentation of PD-1 to sustain T cell exhaustion in lung cancer von Kuo, Wan-Ting, Kuo, I-Ying, Hsieh, Hung-Chia, Wu, Ssu-Ting, Su, Wu-Chou, Wang, Yi-Ching

Volltext

Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial von Yang, James Chih-Hsin, Prof, Shih, Jin-Yuan, MD, Su, Wu-Chou, Prof, Hsia, Te-Chun, MD, Tsai, Chun-Ming, Prof, Ou, Sai-Hong Ignatius, MD, Yu, Chung-Jen, Prof, Chang, Gee-Chen, MD, Ho, Ching-Liang, MD, Sequist, Lecia V, MD, Dudek, Arkadiusz Z, MD, Shahidi, Mehdi, MD, Cong, Xiuyu Julie, PhD, Lorence, Robert M, MD, Yang, Pan-Chyr, Prof, Miller, Vincent A, Dr

Volltext

Cost‐effectiveness of first‐line immunotherapies for advanced non‐small cell lung cancer von Yang, Szu‐Chun, Ou, Huang‐Tz, Su, Wu‐Chou, Wang, Shi‐Yi

Volltext

Immune Checkpoint Inhibitor-Induced Myasthenia Gravis von Huang, Yi-Te, Chen, Ya-Ping, Lin, Wen-Chih, Su, Wu-Chou, Sun, Yuan-Ting

Volltext

Psychometric evaluation of the WHOQOL-BREF, Taiwan version, across five kinds of Taiwanese cancer survivors: Rasch analysis and confirmatory factor analysis von Lin, Chung-Ying, Hwang, Jing-Shiang, Wang, Wen-Chung, Lai, Wu-Wei, Su, Wu-Chou, Wu, Tzu-Yi, Yao, Grace, Wang, Jung-Der

Volltext